Microfluidic Generation of Therapeutically Relevant Polycaprolactone (PCL) Microparticles: Computational and Experimental Approaches

Abstract

Drug releasing microparticles play an important role in drug delivery as they can be used for site specific delivery as well as control over the release time of therapeutics. The use of microfluidic technologies for the fabrication of these particles is of increasing interest since they provide enhanced control over microparticle size and size distribution compared to bulk production methods. However, the use of microfluidic platforms in the production of drug releasing microparticles with therapeutically relevant cargo still requires optimization depending on their application, and the effect of the addition of cargo on the production process is still unexplored. Here we show the formation of therapeutically relevant (in terms of size and dose of cargo) polycaprolactone (PCL) microparticles using a microfluidic platform and analyze the effect of the addition of cargo in the microparticle size and size distribution. This microfluidic platform was designed with the aid of computational fluid dynamic simulations, allowing us to construct a polydimethylsiloxane (PDMS) microfluidic device capable of making microparticles in the range of 15 to 35 μm with low coefficient of variation (CV) both with and without cargo by varying the flow rate ratios of the phases used during droplet generation. Our data show the effect of the addition of cargo on the droplet and microparticle sizes and monodispersity. Our fabrication method allows the formation of spherical microparticles, optimal for biomedical applications. In addition, our microfluidic platform can maintain the generation of monodisperse droplets (with an average size of 52.5 μm) over extended periods of time, suggesting it has the capacity to be used for scaled-up production of PCL microparticles. This microfluidic device is a robust and reliable method for the fabrication of PCL microparticles with cargo, which can potentially be loaded with other relevant therapeutic molecules for biomedical applications.

3D bioprinting patient-derived induced pluripotent stem cell models of Alzheimer’s disease using a smart bioink

“…This can most likely be attributed to the o/w emulsion method of fabrication. The use of microfluidics in the future for fabrication could help with creating a more monodisperse population (Forigua et al 2022 ). Increased cell viability is often found when growth factor microspheres are incorporated into bioinks (Tan et al 2016 ).…”

Multichamber PLGA Microparticles with Enhanced Monodispersity and Encapsulation Efficiency Fabricated by a Batch‐Microfluidic Hybrid Approach

“…[34][35][36] Emulsion formation in microfluidic systems typically involves three main stages: filling, necking, and pinching off. [37] As the dispersed phase flows through the cross-junction, it encounters the continuous phase, and an immiscible droplet with a narrow neck begins to grow. The droplet grows until a balance between interfacial tension and shear force exerted by the continuous phase is achieved.…”

Microfluidic Templating and Initiator‐Free Photocrosslinking of Protein‐Loaded PCL Microcapsules

“…[27,28] In fact, the use of microfluidics for the preparation of polymer particles has received increasing attention, e.g. some literature reports are available describing the microfluidic preparation of non-crosslinked monolithic PCL particles [29,30] and PCL capsules. [31] As summarized in recent reviews (e.g., ref.…”